Curry v. Hansen Medical, Inc. et al
Filing
59
ORDER GRANTING MOTION 33 TO DISMISS SECOND CONSOLIDATED AMENDED COMPLAINT WITH LEAVE TO AMEND. Signed by Judge Jeremy Fogel on August 25, 2011. (jflc1S, COURT STAFF) (Filed on 8/25/2011)
1
**E-Filed 8/25/2011**
2
3
4
5
6
IN THE UNITED STATES DISTRICT COURT
7
FOR THE NORTHERN DISTRICT OF CALIFORNIA
8
SAN JOSE DIVISION
9
10
11
ROBERT CURRY, Individually and on behalf of all
others similarly situated,
Plaintiff,
12
v.
13
14
HANSEN MEDICAL, INC., FREDERIC H. MOLL,
STEVEN M. VAN DICK, and GARY C. RESTANI,
15
Case Number 5:09-cv-05094-JF (HRL)
ORDER1 GRANTING MOTION TO
DISMISS SECOND
CONSOLIDATED AMENDED
COMPLAINT WITH LEAVE TO
AMEND
[Re: Docket No. 33]
Defendants.
16
17
18
19
20
21
22
Lead Plaintiffs Mina and Nader Farr,2 together with other named plaintiffs, bring this
putative class action on behalf of the shareholders of Hansen Medical, Inc. (“Hansen”) who
purchased or acquired common stock in Hansen between February 19, 2008 and October 18,
2009 (the “Class Period”). Plaintiffs allege that Hansen and its officers Frederic H. Moll
(“Moll”), Steven M. Van Dick (“Van Dick”), and Gary C. Restani (“Restani”) (collectively the
“Individual Defendants”) induced them to acquire common stock at artificially inflated prices
23
24
1
25
2
26
27
28
This disposition is not designated for publication.
On February 25, 2010, the Court issued an order consolidating this action with two
related putative class actions–Livingstone v. Hansen Medical, Inc. et al., C 09-5212-JW and
Prenter v. Hansen Medical, Inc. et al., C 09-5367-CRB. Order Granting Motion to Consolidate,
Dkt. 15. In that order, the Court also granted a request that Mina and Nader Farr be appointed
lead plaintiffs, as they suffered the largest alleged economic loss and otherwise fulfilled the
requirements for appointment as lead plaintiffs. Id.
Case Number 5:09-cv-05094-JF (HRL)
ORDER GRANTING MOTION TO DISMISS SECOND CONSOLIDATED AMENDED COMPLAINT WITH
LEAVE TO AMEND
(JFLC1)
1
during the Class Period by making knowing and intentional misstatements regarding Hansen’s
2
revenue recognition and sales performance, in violation of §§ 10(b) and 20(a) of the Securities
3
Exchange Act of 1934, 15 U.S.C. §§ 78j(b), 78t(a) (the “Exchange Act”) and Rule 10b-5, 17
4
C.F.R. § 240.10b-5 promulgated thereunder.
Pursuant to Fed. R. Civ. P. 12(b)(6), Defendants move to dismiss Plaintiffs’ Second
5
6
Consolidated Amended Complaint (“SCAC”)3 on the basis that Plaintiffs have not alleged
7
securities fraud with sufficient particularity. The Court has reviewed the moving and responding
8
papers and has considered the oral argument of counsel presented at the hearing. For the reasons
9
set forth below, the Court agrees with Defendants that Plaintiffs have not satisfied the heightened
10
pleading requirements of Fed. R. Civ. P. 9(b) and the Private Securities Litigation Reform Act of
11
1995, 15 U.S.C. § 78u-4(b)(1)-(2) (“PSLRA”). Accordingly, the motion to dismiss will be
12
granted, with leave to amend.
I. BACKGROUND
13
14
A.
Hansen
15
Hansen designs, manufactures, and sells medical robotics, including the Sensei Robotic
16
Catheter System (referred to herein as “Sensei” or the “System”)–a robotic system that enables
17
physicians to navigate flexible catheters. SCAC ¶¶ 2-3. Hansen derives the bulk of its revenue
18
from Sensei sales. Id. at ¶ 3. Hansen became a public company in 2006, and it recognized its
19
first revenues in the second quarter of 2007, when it launched the Sensei system commercially.
20
Id. The company’s revenue recognition policy for Sensei sales is based on American Institute of
21
Certified Public Accountants, Statement of Position 97-2, Software Revenue Recognition (“SOP
22
97-2”). Ex. 24 to Defendants’ Request for Judicial Notice (hereinafter referred to as “RJN”).
23
Pursuant to SOP 97-2, Hansen recognizes system revenues only after installation of the product
24
and training are complete. Id.
25
3
26
27
28
The parties stipulated previously to the filing of a consolidated first amended complaint
and the operative second consolidated amended complaint. See April 26, 2010 Stipulation and
Order Re Filing of a Consolidated Amended Complaint, Dkt. 21; July 15, 2010 Stipulation and
Order Re Filing of a Second Consolidated Amended Complaint, Dkt. 27.
2
Case Number 5:09-cv-05094-JF (HRL)
ORDER GRANTING MOTION TO DISMISS SECOND CONSOLIDATED AMENDED COMPLAINT WITH
LEAVE TO AMEND
(JFLC1)
1
B.
Internal Investigation
In August 2009, an anonymous “whistleblower” informed Hansen that an irregularity in a
2
3
single Sensei transaction had led to improper revenue recognition in the fourth quarter of 2008.
4
See, e.g., SCAC ¶¶ 290, 294, 296. An investigation conducted by Hansen’s audit committee in
5
conjunction with independent outside counsel concluded that sales data on certain transactions
6
was withheld from Hansen’s accounting department and independent auditors. See, e.g., Id. at ¶¶
7
294, 296. The investigation also concluded that documents related to certain revenue were
8
falsified and that as a result Hansen’s accounting department had incomplete information
9
regarding temporary installations, unfulfilled training obligations, and undisclosed side
10
arrangements. Id. Additionally, the investigation raised questions with respect to the ability of
11
Hansen’s distributors to install systems and train end-users independently. Id. These findings
12
initially were made public in Hansen’s Form 8-K filed with the Securities and Exchange
13
Commission (“SEC”) on October 19, 2009. Id. at ¶ 290.
14
C.
The Restatement
15
On November 16, 2009, after learning of the improper revenue recognition, Hansen
16
restated its financial statements for the year ended December 31, 2008, and for the quarters
17
ended March 31, June 30, and September 30, 2008, as well as March 31 and June 30, 2009. See,
18
e.g., Id. at ¶¶ 289, 295-96. Plaintiffs claim that the misstatements disclosed in the Restatement
19
were made knowingly and intentionally as part of a scheme to inflate stock prices. They base
20
this assertion primarily upon the following: (1) information provided by confidential witnesses
21
who were employed by Hansen; (2) the magnitude of the accounting errors that led to the
22
Restatement, and (3) the Individual Defendants’ routine interaction with Hansen’s core
23
operations.
24
II. STANDARD OF REVIEW
25
“Dismissal under Rule 12(b)(6) is appropriate only where the complaint lacks a
26
cognizable legal theory or sufficient facts to support a cognizable legal theory.” Mendiondo v.
27
Centinela Hosp. Med. Ctr., 521 F.3d 1097, 1104 (9th Cir. 2008). For purposes of a motion to
28
3
Case Number 5:09-cv-05094-JF (HRL)
ORDER GRANTING MOTION TO DISMISS SECOND CONSOLIDATED AMENDED COMPLAINT WITH
LEAVE TO AMEND
(JFLC1)
1
dismiss, the plaintiff's allegations are taken as true, and the court must construe the complaint in
2
the light most favorable to the plaintiff. Jenkins v. McKeithen, 395 U.S. 411, 421 (1969). “To
3
survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true,
4
to ‘state a claim to relief that is plausible on its face.’ A claim has facial plausibility when the
5
plaintiff pleads factual content that allows the court to draw the reasonable inference that the
6
defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 129 S.Ct. 1937, 1949 (2009),
7
Bell Atl. Corp. v. Twombly, 550 U.S. 544, 556 (2007). Thus, a court need not accept as true
8
conclusory allegations, unreasonable inferences, legal characterizations, or unwarranted
9
deductions of fact contained in the complaint. Clegg v. Cult Awareness Network, 18 F.3d 752,
10
754-55 (9th Cir. 1994). Leave to amend must be granted unless it is clear that the complaint's
11
deficiencies cannot be cured by amendment. Lucas v. Dep’t of Corr., 66 F.3d 245, 248 (9th Cir.
12
1995). When amendment would be futile, however, dismissal may be ordered with prejudice.
13
Dumas v. Kipp, 90 F.3d 386, 393 (9th Cir. 1996).
III. DISCUSSION
14
15
A.
Section 10(b) Claim
16
SEC Rule 10b-5, promulgated under § 10(b) of the Exchange Act “prohibits, in
17
connection with the purchase or sale of any security, the making of any untrue statement of a
18
material fact or the omission of a material fact that would render statements made not
19
misleading.” Basic Inc. v. Levinson, 485 U.S. 224, 224 (1988); 15 U.S.C. § 78j(b); 17 C.F.R. §
20
240.10b-5. Although the Exchange Act does not expressly create a private right of action for
21
violations of § 10(b), the Supreme Court “has found a right of action implied in the words of the
22
statute and its implementing regulation.” Stoneridge Inv. Partners, LLC v. Scientific Atlanta,
23
Inc., 552 U.S. 148, 157 (2008) (citing Superintendent of Ins. of N.Y. v. Bankers Life & Casualty
24
Co., 404 U.S. 6, 13 n. 9 (1971)).
25
To state a claim for securities fraud under § 10(b) and Rule 10b-5, a plaintiff must plead
26
“(1) a material misrepresentation or omission by the defendant; (2) scienter; (3) a connection . . .
27
[with] the purchase or sale of a security; (4) reliance . . .; (5) economic loss; and (6) loss
28
4
Case Number 5:09-cv-05094-JF (HRL)
ORDER GRANTING MOTION TO DISMISS SECOND CONSOLIDATED AMENDED COMPLAINT WITH
LEAVE TO AMEND
(JFLC1)
1
causation.” Id.; See also Dura Pharms, Inc. v. Broudo, 544 U.S. 336, 341-42 (2005). “At the
2
pleading stage, a complaint stating claims under section 10(b) and Rule 10b–5 must satisfy the
3
dual pleading requirements of Federal Rule of Civil Procedure 9(b) and the PSLRA.” Zucco
4
Partners, LLC v. Digimarc Corp., 552 F.3d 981, 990 (9th Cir. 2009). Rule 9(b) requires that
5
“[i]n all averments of fraud . . . the circumstances constituting fraud . . . shall be stated with
6
particularity.” Fed. R. Civ. P. 9(b). Plaintiffs must state “the who, what, when, where, and how
7
of the misconduct charged.” Kearns v. Ford Motor Co., 567 F.3d 1120, 1124 (9th Cir. 2009).
8
Additionally, the PSLRA requires that both falsity and scienter be pled with particularity.
9
Zucco, 552 F.3d at 990; Ronconi v. Larkin, 253 F.3d 423, 429 (9th Cir. 2001).
10
1.
Misrepresentations
11
A securities fraud complaint must “specify each statement alleged to have been
12
misleading, the reason or reasons why the statement is misleading, and, if an allegation regarding
13
the statement or omission is made on information and belief, . . . state with particularity all facts
14
on which that belief is formed.” Gompper v. VISX, Inc., 298 F.3d 893, 895 (9th Cir. 2002),
15
(quoting 15 U.S.C. § 78u–4(b)(1)). “For purposes of Rule 10b–5, the maker of a statement is the
16
person or entity with ultimate authority over the statement, including its content and whether and
17
how to communicate it.” Janus Capital Group, Inc. v. First Derivative Traders, 131 S.Ct. 2296,
18
2302 (2011).
19
The PSLRA provides a safe harbor for forward-looking statements that are accompanied
20
by meaningful cautionary language. 15 U.S.C. § 78u–5. Under the statute, a forward-looking
21
statement is defined as:
22
(A) a statement containing a projection of revenues, income (including income
23
loss), earnings (including earnings loss) per share, capital expenditures,
24
dividends, capital structure, or other financial items;
25
(B) a statement of the plans and objectives of management for future operations,
26
including plans or objectives relating to the products or services of the issuer;
27
(C) a statement of future economic performance, including any such statement
28
5
Case Number 5:09-cv-05094-JF (HRL)
ORDER GRANTING MOTION TO DISMISS SECOND CONSOLIDATED AMENDED COMPLAINT WITH
LEAVE TO AMEND
(JFLC1)
1
contained in a discussion and analysis of financial condition by the management
2
or in the results of operations included pursuant to the rules and regulations of the
3
Commission;
4
(D) any statement of the assumptions underlying or relating to any statement
5
described in subparagraph (A), (B), or (C);
6
(E) any report issued by an outside reviewer retained by an issuer, to the extent
7
that the report assesses a forward-looking statement made by the issuer; or
8
(F) a statement containing a projection or estimate of such other items as may be
9
specified by rule or regulation of the Commission.
10
11
15 U.S.C. § 78u-5(c).
Plaintiffs allege that during the Class Period, Defendants issued misleading statements in
12
press releases, SEC filings, and conference calls with market participants. SCAC ¶¶ 58-288.
13
For example, Plaintiffs allege that during a conference call in the second quarter of 2009, Moll
14
told investors that Hansen had experienced “four successive quarters of increasing sales in
15
catheters in service.” Id. at ¶ 274. During that same call, Moll allegedly painted an overly-
16
generous picture of utilization rates, stating “[o]n a positive note, we have had a number of users
17
able to accomplish three procedures a day, and some very active users are accomplishing six
18
procedures a week.” Id. Plaintiffs claim that statements like these led investors to believe that
19
Hansen’s Sensei sales and utilization rates were stable when in fact they were declining.
20
Statements of present or historical fact are not protected by the PSLRA safe harbor. See
21
In re Portal Software, Inc. Sec. Litig., No. 03-cv-5138 VRW, 2005 WL 1910923, at * 13 (Aug.
22
10, 2005) (citing Livid Holdings Ltd. v. Salomon Smith Barney, Inc., 403 F.3d 1050, 1056-57
23
(9th Cir. 2005)) ( “[N]either the PSLRA’s safe harbor provision nor the bespeaks caution
24
doctrine are applicable to statements of historical fact.”). Thus, references to concrete rates of
25
Sensei sales and user activity would not be immune. However, where Defendants gave
26
projections such as “none of us have a crystal ball, but we feel very confident that given the
27
pipeline . . . we’re going to have a very reason able [sic] 2009” these would fall within the
28
6
Case Number 5:09-cv-05094-JF (HRL)
ORDER GRANTING MOTION TO DISMISS SECOND CONSOLIDATED AMENDED COMPLAINT WITH
LEAVE TO AMEND
(JFLC1)
1
2
forward-looking statements contemplated by the safe harbor provision. SCAC ¶ 193.
Whether or not the PSLRA affords protection to Defendants, no statement is actionable
3
unless it is alleged to have been made with actual knowledge of its falsity. 15 U.S.C. §
4
78u-5(c)(1)(B). Plaintiffs cannot rely on “[a] series of conclusory allegations that Defendants
5
knew or recklessly disregarded the falsity of their statements.” In re Jones Soda Co. Sec. Litig.,
6
393 Fed. Appx. 507, 509 (9th Cir. 2010). For the reasons discussed below, Plaintiffs have not
7
pled sufficient facts to show that the alleged misstatements were made with the requisite
8
knowledge.
9
10
2.
Scienter
“Scienter is the ‘mental state embracing intent to deceive, manipulate, or defraud.’” SEC
11
v. Todd, et al., 642 F.3d 1207, 1215 (9th Cir. 2011) (quoting Ernst & Ernst v. Hochfelder, 425
12
U.S. 185, 193 n. 12 (1976)). “Reckless conduct may also constitute scienter.” Id. (citing SEC v.
13
Dain Rauscher, Inc., 254 F.3d 852, 856 (9th Cir. 2001)). When analyzing scienter in connection
14
with § 10(b) violations, courts in the Ninth Circuit must conduct a dual inquiry in accordance
15
with the Supreme Court’s decision in Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308
16
(2007). See Zucco, 552 F.3d at 992. First, courts must “determine whether any of the plaintiff’s
17
allegations, standing alone, are sufficient to create a strong inference of scienter; second, if no
18
individual allegations are sufficient, [courts must]. . . conduct a ‘holistic’ review of the same
19
allegations to determine whether the insufficient allegations combine to create a strong inference
20
of intentional conduct or deliberate recklessness.” Id.
21
22
a.
Confidential Witnesses
Witness accounts can give rise to a strong inference of scienter if: (1) witnesses are
23
“described in the complaint with sufficient particularity to support the probability that a person
24
in the position occupied by the source would possess the information alleged;” and (2) the
25
statements attributed to witnesses are indicative of scienter. In re Daou Sys., Inc., 411 F.3d
26
1006, 1015-16 (9th Cir. 2005). The Ninth Circuit concluded in Zucco that allegations made by
27
witnesses who were not employed throughout the length of the relevant time period were
28
7
Case Number 5:09-cv-05094-JF (HRL)
ORDER GRANTING MOTION TO DISMISS SECOND CONSOLIDATED AMENDED COMPLAINT WITH
LEAVE TO AMEND
(JFLC1)
1
unreliable. Id., 552 F.3d at 996-97; See also Brodsky v. Yahoo! Inc., 630 F. Supp. 2d 1104, 1115
2
(N.D. Cal. 2009) (“[B]ecause CW 3 and CW 5 were not Yahoo! employees for most of the Class
3
Period, the Court cannot rely on their statements to support claims of false revenue reporting for
4
the entire Class Period.”).
5
The SCAC sets forth accounts from twelve confidential witnesses (“CWs”). SCAC ¶¶
6
34-45. However, only one of the twelve was employed by Hansen throughout the entirety of the
7
Class Period. See, e.g., Id. at ¶¶ 37, 39 (“CW4 was employed by Hansen as a Clinical Account
8
Manager from approximately April 2007 to approximately July 2009. . . CW6 was the senior
9
director of the Company’s Structural Heart Division from approximately December 2007 to
10
approximately September 2008.”). Moreover, none of the witnesses is alleged to have worked
11
directly with revenue recognition. Several worked in sales and clinical accounts. See, e.g., Id. at
12
¶¶ 37-38, 40, 43-44. There at least is a colorable argument that none of these individuals would
13
have been in a position to know whether the Individual Defendants knew or should have known
14
of Hansen’s improper recognition of revenue.
15
In addition, certain allegations rely on hearsay and even at face value fail to demonstrate
16
that the Individual Defendants had knowledge of the alleged fraudulent activity. For example,
17
several CWs claim to have “heard” that Hansen installed a Sensei system at Yale just before the
18
end of the fourth quarter in 2008 and immediately uninstalled it after reporting revenue from the
19
transaction. See, e.g., Id. at ¶¶ 37(g) (“CW 4 was told by his/her boss that Hansen had recorded
20
revenue on a System installed at Yale . . . to make the revenue numbers for the quarter look
21
good.”). Although two CWs confirm that these events took place, neither of them indicates that
22
the Individual Defendants were made aware of the problem. Id. ¶¶ 34, 40.
23
The most compelling allegations come from CW1, the only witness who was employed
24
throughout the Class Period. CW1 allegedly worked with customer support and managed
25
installations. Id. ¶ 34. As a part of these duties, CW1 was required to attend weekly installation
26
meetings with Van Dick and Moll that centered on reports showing “customers line-by-line with
27
columns for the purchase order, the installation dates, and the training dates.” Id. at ¶ 34(a)(i).
28
8
Case Number 5:09-cv-05094-JF (HRL)
ORDER GRANTING MOTION TO DISMISS SECOND CONSOLIDATED AMENDED COMPLAINT WITH
LEAVE TO AMEND
(JFLC1)
1
CW1 goes on to state that during his tenure, there were several incomplete transactions for which
2
revenue should have been deferred, but he does not claim specifically that this information was
3
made known to Defendants in the line-by-line reports or that it was communicated to them
4
verbally at the weekly meetings. Id. at ¶¶ 34(e)-(p). CW1 states only that “catheter sales
5
generally would be talked about as much as System sales in the installation and sales meetings;”
6
but this does not account for the problem outlined in the Restatement, which is that Defendants
7
were receiving false information and incomplete data on sales. Id. at ¶ 34(q). Perhaps Plaintiffs
8
are claiming that the lack of catheter sales to Sensei purchasers should have alerted Defendants
9
to the reality that a large number of Sensei systems were not in use–the implication being that
10
users would need additional catheter supplies. However, while this might be suggestive of
11
willful ignorance on Defendants’ part, the argument is entirely circumstantial and does not
12
support a strong inference of scienter.
13
14
b.
Core Operations
A defendant’s knowledge of core business operations may satisfy the PSLRA scienter
15
requirement if it is alleged that the defendant “had actual access to the disputed information . . .
16
or where the nature of the relevant fact is of such prominence that it would be ‘absurd’ to suggest
17
that management was without knowledge of the matter.” South Ferry LP, No. 2 v. Killinger, 542
18
F.3d 776, 786 (9th Cir. 2008).
19
Here, Plaintiffs allege that the Individual Defendants were involved heavily in Hansen’s
20
daily operations and admitted as much on several occasions. Restani, the Chief Operating
21
Officer, allegedly stated that Hansen had “a pipeline of opportunity” that Defendants “mind[ed]
22
constantly every day.” SCAC ¶ 71. And, Chief Executive Officer Moll boasted that Defendants
23
“study” Sensei utilization because they “want to be all over that” in order to determine how to
24
realize full utilization more quickly. Id. ¶ 157.
25
Plaintiffs contend that at the very least Defendants were deliberately reckless in not
26
knowing of Hansen’s non-compliance with its own revenue recognition policy. However, the
27
facts alleged in the SCAC depict a situation more akin to that in Zucco, where corporate officers’
28
9
Case Number 5:09-cv-05094-JF (HRL)
ORDER GRANTING MOTION TO DISMISS SECOND CONSOLIDATED AMENDED COMPLAINT WITH
LEAVE TO AMEND
(JFLC1)
1
alleged access to manipulated accounting data did not “support the inference that management
2
was in a position to know that such data was being manipulated.” 552 F.3d at 1000-01.
3
Plaintiffs also argue that Defendants should have been aware of improper channel
4
stuffing.4 They make numerous allegations, many of which come from the CWs, that Hansen
5
pressured sales before the close of each quarter. See, e.g., SCAC ¶¶ 37, 42. Plaintiffs assert that
6
consistent spikes in quarter-end sales and the uninstallation of the Yale system one week after it
7
was installed should have put the Individual Defendants on notice that Hansen was engaging in
8
this illegal practice. However, “there is nothing inherently improper in pressing for sales to be
9
made earlier than in the normal course.” Greebel v. FTP Software, 194 F.3d 185, 202-03 (1st
10
Cir. 1999); Broudo v. Dura Pharms., Inc., 339 F.3d 933, 940 (9th Cir. 2003), rev’d on other
11
grounds by 544 U.S. 336 (2005). Additionally, the SCAC does not plead with particularity that
12
Defendants were aware of the alleged uninstallation at Yale.
c.
13
14
Magnitude of the Restatement and GAAP Violations
Plaintiffs claim that Hansen’s improper recognition of revenue on twenty-four of fifty-
15
nine Sensei systems sold over seven reporting periods is sufficient to establish scienter. See
16
SCAC ¶ 299. As the Ninth Circuit reiterated recently in Todd, 642 F.3d at 1218, while GAAP
17
violations generally are not probative of scienter, “significant violations of GAAP, taking place
18
over an extended period of time, give rise to a strong inference of scienter.” Batwin v. Occam
19
Networks, Inc., No. C 07-2750, 2008 WL 2676364, at *13 (C.D. Cal. July 1, 2008). Indeed,
20
courts have found scienter where “no accountant ‘would have made the same decisions if
21
confronted with the same facts.’” In re Medicis Pharm. Corp. Sec. Litig., 689 F. Supp. 2d 1192,
22
1205-06 (D. Ariz. 2009) (quoting In re Software Toolworks, Inc. Sec. Litig., 50 F.3d 615, 628
23
(9th Cir. 1994)). However, it is not apparent from the specific facts alleged in the SCAC that the
24
accounting mistakes made by Hansen here were so egregious that the Individual Defendants
25
26
27
4
The term “channel stuffing” refers to the improper recording of sales in one quarter that
is later reversed–and revenues reduced–upon the customer’s return of a product it could not sell
or use and never had any intention of keeping. Mot. at 16.
28
10
Case Number 5:09-cv-05094-JF (HRL)
ORDER GRANTING MOTION TO DISMISS SECOND CONSOLIDATED AMENDED COMPLAINT WITH
LEAVE TO AMEND
(JFLC1)
1
must have been aware of them. This especially is true in light of the fact that Hansen’s internal
2
investigation found that the accountants had been given incorrect information. See SCAC ¶ 296
3
(“The audit committee’s investigation determined that information was withheld from the
4
Company’s accounting department and independent auditors. . .”).
5
6
d.
SOX Certifications
Certifications made pursuant to the Sarbanes-Oxley Act of 2002 (“SOX”), 15 U.S.C. §
7
7201, et seq., can raise an inference of scienter “if the person signing the certification was
8
severely reckless in certifying the accuracy of the financial statements.” Glazer Capital
9
Management, LP v. Magistri, 549 F.3d 736, 747 (9th Cir. 2008). Moll and Van Dick signed
10
numerous SOX certifications attesting to the strength of Hansen’s financial condition and the
11
effectiveness of Hansen’s internal controls. See, e.g., SCAC ¶¶ 30, 31, 58. However, Glazer
12
cautions that if courts were to rely solely on SOX certifications, “scienter would be established
13
in every case where there was an accounting error . . . thereby eviscerating the pleading
14
requirements for scienter set forth in the PSLRA.” 549 F.3d at 747. The facts alleged in the
15
SCAC do not demonstrate that Defendants were aware of improper revenue recognition at the
16
time the SOX certifications were made. The fact that Defendants acknowledged in the
17
Restatement that certain revenue should have been deferred does not indicate that they were
18
withholding this information from investors.
19
e.
Equity Offerings
20
Plaintiffs claim that Defendants’ decision to conduct two public equity offerings during
21
the Class Period shows a motivation to raise capital through artificial means. In April 2008 and
22
April 2009, Defendants completed two public offerings each of which earned the company more
23
than $30 million. SCAC ¶¶ 320-21. Although Plaintiffs question the timing of the offerings,
24
alleging that the April 2008 offering came on the heels of Hansen’s first overstated financial
25
results and that the April 2009 offering was made just months before Hansen announced the
26
Restatement, their allegations do not establish scienter. It is clear that in the Ninth Circuit
27
private securities plaintiffs cannot aver intent in general terms of mere “motive and opportunity.”
28
11
Case Number 5:09-cv-05094-JF (HRL)
ORDER GRANTING MOTION TO DISMISS SECOND CONSOLIDATED AMENDED COMPLAINT WITH
LEAVE TO AMEND
(JFLC1)
1
South Ferry, 542 F.3d at 782 (quoting In re Silicon Graphics Inc. Sec. Litig., 183 F.3d 970, 979
2
(9th Cir. 1999)); See also In re Calpine Corp. Sec. Litig., 288 F. Supp. 2d 1054, 1087 (N.D. Cal.
3
2003) (“[A]llegations of a motive to present better financial statements to secure credit or to
4
engage in similar business activities are insufficient to establish a strong inference of scienter.”).
f.
5
Totality of the Allegations
As indicated above, “Tellabs permits a series of less precise allegations to be read
6
7
together to meet the PSLRA requirement.” South Ferry, 542 F.3d at 784 (citing 551 U.S. 308
8
(2007)). However, “[e]ven if a set of allegations may create an inference of scienter greater than
9
the sum of its parts, it must still be at least as compelling as an alternative innocent explanation.”
10
Zucco, 552 F.3d at 1006. Despite the length of the SCAC, Plaintiffs’ allegations taken together
11
do not preclude the possibility that Defendants were unaware of the inflated revenue because
12
they were provided with false information. Plaintiffs have laid a foundation for their 10(b)
13
claim, but additional specificity is needed to show that Defendants acted with the requisite
14
mental state. Because the Court concludes that Plaintiffs have not alleged scienter, it need not
15
address the remaining claim requirements.
16
B.
17
Section 20(a) Claim
Plaintiffs assert that Defendants acted as control persons within the meaning of § 20(a) of
18
the Exchange Act. 15 U.S.C. § 78t(a). Under § 20(a), “a defendant may be liable for securities
19
violations if (1) there is a violation of the Act and (2) the defendant directly or indirectly controls
20
any person liable for the violation.” Todd, 642 F.3d at 1223 (citing Howard v. Everex Sys., Inc.,
21
228 F.3d 1057, 1065 (9th Cir. 2000)).5 Because no securities fraud claim has been stated,
22
Plaintiffs’ 20(a) claim also is subject to dismissal.
IV. ORDER
23
24
25
Good cause therefor appearing, the motion to dismiss is GRANTED, WITH LEAVE TO
AMEND. Defendants’ request for judicial notice is granted as to the Statement of Position
26
27
5
The definition of the term “person” under the Act encompasses a company. 15 U.S.C. §
78c(a)(9).
28
12
Case Number 5:09-cv-05094-JF (HRL)
ORDER GRANTING MOTION TO DISMISS SECOND CONSOLIDATED AMENDED COMPLAINT WITH
LEAVE TO AMEND
(JFLC1)
1
identified in Ex. 24.6 Any amended pleading shall be filed within thirty (30) days from the date
2
of this Order.
3
4
IT IS SO ORDERED.
5
6
DATED: August 25, 2011
____________________________
JEREMY FOGEL
United States District Judge
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
6
The Court otherwise has not relied upon the parties’ requests for judicial notice in
reaching the conclusions herein.
28
13
Case Number 5:09-cv-05094-JF (HRL)
ORDER GRANTING MOTION TO DISMISS SECOND CONSOLIDATED AMENDED COMPLAINT WITH
LEAVE TO AMEND
(JFLC1)
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?